Willis Investment Counsel Purchases 1,156 Shares of Eli Lilly and Company $LLY

Key Points

• Willis Investment Counsel raised its stake in Eli Lilly by 5.8%, buying 1,156 shares to own 20,926 shares worth about $22.49 million, as institutional investors hold roughly 82.5% of the stock.
• Eli Lilly posted strong quarterly results—$7.54 EPS and $19.29 billion revenue (up 42.6% YoY), beating estimates—and set FY2026 guidance of 33.500–35.000 EPS.
• The company is ramping commercialization of its oral GLP‑1 pill Foundayo through pharmacy and Amazon partnerships, supporting growth, but faces pricing pressure and generic competition in markets like India that could weigh on international sales.

Willis Investment Counsel increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,926 shares of the company's stock after acquiring an additional 1,156 shares during the period. Willis Investment Counsel's holdings in Eli Lilly and Company were worth $22,489,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Exencial Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after acquiring an additional 11,396 shares during the period. Rede Wealth LLC bought a new position in shares of Eli Lilly and Company in the 3rd quarter worth $487,000. Central Pacific Bank Trust Division increased its holdings in shares of Eli Lilly and Company by 25.8% in the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock worth $6,859,000 after buying an additional 1,843 shares during the last quarter. Cidel Asset Management Inc. increased its holdings in shares of Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after buying an additional 5,591 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after buying an additional 592 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.0%

Shares of LLY opened at $939.79 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market capitalization of $887.93 billion, a P/E ratio of 40.95, a PEG ratio of 1.09 and a beta of 0.51. The firm has a fifty day simple moving average of $984.00 and a two-hundred day simple moving average of $977.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the business earned $5.32 EPS. The company's revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo commercial launch and broad distribution—Lilly has officially launched oral GLP‑1 pill Foundayo and is rapidly expanding access through pharmacy and telehealth partners (GoodRx, WeightWatchers, LillyDirect and traditional pharmacies), which should accelerate patient uptake and revenue diversification. LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
• Positive Sentiment: Amazon & same‑day delivery tie‑ups broaden access—Amazon Pharmacy and kiosks will stock Foundayo and offer same‑day/next‑day delivery, lowering friction for prescriptions and increasing potential volume. This distribution boost is bullish for top‑line growth. Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery
• Positive Sentiment: Bullish analyst action—Morgan Stanley raised its price target and kept an overweight rating, signaling continued confidence in Lilly’s growth trajectory from obesity drugs and pipeline strength. Benzinga coverage of analyst action
• Neutral Sentiment: Mixed analyst views—Rothschild & Co Redburn nudged its target slightly but maintained a neutral stance, reflecting debate over near‑term pricing and margins despite long‑term opportunity. Rothschild & Co Redburn adjusts price target on Eli Lilly
• Negative Sentiment: Competitive and pricing pressure in India—Cheap generic semaglutide copies in India have reduced Lilly’s market share there, a first sign that pricing pressure and generic erosion could weigh on international sales. Eli Lilly slips as generics flood India
• Negative Sentiment: Market‑share softness as the GLP‑1 market intensifies—Reports show Lilly’s share dipping amid aggressive competition (including Novo) and cheaper alternatives, which raises near‑term revenue uncertainty. Eli Lilly’s Market Share Dips as Weight-Loss Drug War Heats Up

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LLY shares. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Freedom Capital raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Tuesday, February 10th. The Goldman Sachs Group set a $1,260.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Truist Financial reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Finally, Bank of America upped their price objective on shares of Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a "buy" rating in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,224.59.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.